Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... year to $13.5 billion from $9.3 billion. Earnings per share came in at $4.99, underperforming Wall ...

Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes ... between $22.50 and $24.00 per share on an adjusted basis this ...

On TikTok, where the 31-year-old mother of three chronicled her weight loss journey ... ovarian syndrome (PCOS), her doctor prescribed Zepbound to help with symptoms of the condition as well ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

open image in gallery A small percentage of patients taking weight loss and diabetes drugs like Ozempic and Zepbound have experienced ... and Wegovy, as per the approved labels.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs ... who was attending boot camp five days a week, was at her thinnest — 160 pounds.

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Since then, Novo Nordisk (Wegovy and Ozempic) and Eli Lilly (Mounjaro and Zepbound ... As per a Wired report, many consumers, in turn, have jumped at the chance to get cheaper weight loss drugs ...

The drugmaker's shares were up nearly 5% at $882 in afternoon trading. The stock has more than doubled in value in the last two years, making it the most valuable healthcare company in the world, but ...